These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 2245807

  • 1. Lack of substantial five year disease-free survival by primary aggressive surgery and cisplatin-based chemotherapy or by salvage intraperitoneal cisplatin-based chemotherapy.
    Piver MS, Baker TR, Driscoll DL.
    Eur J Gynaecol Oncol; 1990; 11(4):243-50. PubMed ID: 2245807
    [No Abstract] [Full Text] [Related]

  • 2. [Prognostic factors of common epithelial ovarian cancer treated by surgery and cisplatin based combination chemotherapy].
    Sasaki H, Ochiai K, Terashima Y, Mochizuki S, Soda T, Nishimura H, Yakushiji M, Hirabayashi M.
    Gan No Rinsho; 1989 Oct; 35(13):1615-20. PubMed ID: 2585733
    [Abstract] [Full Text] [Related]

  • 3. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC.
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [Abstract] [Full Text] [Related]

  • 4. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
    Barakat RR, Fennelly D, Pizzuto F, Venkatraman ES, Brown C, Curtin JP.
    Eur J Gynaecol Oncol; 1997 Jan; 18(3):161-3. PubMed ID: 9174826
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 6. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
    Wils J, Blijham G, Naus A, Belder C, Boschma F, Bron H, Ceelen T, Eekhout A, von Erp J, Geelen P.
    J Clin Oncol; 1986 Jul 15; 4(7):1068-73. PubMed ID: 3723166
    [Abstract] [Full Text] [Related]

  • 7. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE.
    Eur J Gynaecol Oncol; 1998 Jul 15; 19(1):5-10. PubMed ID: 9476049
    [Abstract] [Full Text] [Related]

  • 8. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
    Li M, Huang X.
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct 15; 31(10):621-3. PubMed ID: 9275460
    [Abstract] [Full Text] [Related]

  • 9. Intraperitoneal cisplatin with intravenous cyclophosphamide and doxorubicin for previously untreated stage III and IV ovarian carcinoma.
    Young JA, Garretson F, Westlake DL, Illig WP, Vogl SE.
    Cancer Invest; 1989 Oct 15; 7(6):565-70. PubMed ID: 2630007
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.
    Int J Gynecol Cancer; 2012 Jun 15; 22(5):778-85. PubMed ID: 22572845
    [Abstract] [Full Text] [Related]

  • 11. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
    Venesmaa P.
    Obstet Gynecol; 1994 Jul 15; 84(1):8-11. PubMed ID: 8008329
    [Abstract] [Full Text] [Related]

  • 12. Intraperitoneal doxorubicin in combination with systemic cisplatinum and cyclophosphamide in the treatment of stage III ovarian cancer.
    Deppe G, Malviya VK, Boike G, Young J.
    Eur J Gynaecol Oncol; 1991 Jul 15; 12(2):93-7. PubMed ID: 2055231
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils J, van Geuns H.
    Am J Clin Oncol; 1989 Jun 15; 12(3):251-4. PubMed ID: 2658540
    [Abstract] [Full Text] [Related]

  • 14. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE.
    J Clin Oncol; 1989 Feb 15; 7(2):223-9. PubMed ID: 2915238
    [Abstract] [Full Text] [Related]

  • 15. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M, Mosconi AM, Gori S, Belsanti V, Basurto C, De Angelis V, Giansanti M, Tonato M.
    Am J Clin Oncol; 1997 Oct 15; 20(5):522-6. PubMed ID: 9345342
    [Abstract] [Full Text] [Related]

  • 16. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
    Baker TR, Piver MS, Hempling RE.
    Cancer; 1994 Jul 15; 74(2):656-63. PubMed ID: 8033045
    [Abstract] [Full Text] [Related]

  • 17. First-line chemotherapy with intraperitoneal cisplatin and intravenous cyclophosphamide in ovarian carcinoma. A preliminary report.
    Zambetti M, Gianni L, Escobedo A, Pizzetti P, Spatti GB, Bonadonna G.
    Am J Clin Oncol; 1989 Apr 15; 12(2):118-22. PubMed ID: 2705400
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group.
    N Engl J Med; 2006 Jan 05; 354(1):34-43. PubMed ID: 16394300
    [Abstract] [Full Text] [Related]

  • 19. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B.
    N Engl J Med; 1996 Dec 26; 335(26):1950-5. PubMed ID: 8960474
    [Abstract] [Full Text] [Related]

  • 20. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care.
    Acta Oncol; 2001 Dec 26; 40(2-3):340-60. PubMed ID: 11441940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.